Risankizumab vs Ustekinumab in Patients With Crohn Disease: Trial Results
Risankizumab is an interleukin-23 antagonist; ustekinumab is an interleukin-12 and -23 antagonist.
Risankizumab is an interleukin-23 antagonist; ustekinumab is an interleukin-12 and -23 antagonist.
According to the FDA, there are no legally marketed ophthalmic products that contain MSM as an active ingredient.
The investigational therapy is designed to decrease the production of soluble fms-like tyrosine kinase-1 (sFLT1) mRNA isoforms in the placenta.
Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
The Motive Knee device is intended to strengthen the quadriceps muscles using neuromuscular electrical stimulation to provide knee pain relief.
Removing the prescription requirement improves access to an effective contraceptive method for women of all ages.
The approval of empagliflozin for pediatric T2DM was based on data from the phase 3 DINAMO trial.
The phase 3 INVIGORATE-2 trial included 131 allergic conjunctivitis patients 18 years of age and older.
The sNDA included 770 patients who have not previously received chemotherapy for mPDAC.
BabySat is expected to be available by prescription later this year.